The influence of estrogen on monoamine oxidase activity

Psychopharmacology Bulletin

Volumn 33, Issue 2, 1997, Pages 229-233

  Chakravorty, Sudeep G ^a   Halbreich, Uriel ^b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

ERT; Estrogen; Hormones; MAO; Monoamine oxidase

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); ESTROGEN; MONOAMINE OXIDASE INHIBITOR;

COGNITION; DEGENERATIVE DISEASE; ENZYME ACTIVITY; ESTROGEN THERAPY; HORMONAL REGULATION; HORMONE ACTION; MENTAL DISEASE; MOOD; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; DEPRESSION; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; HUMANS; MACACA MULATTA; MALE; MONOAMINE OXIDASE; RATS;

EID: 0030740982     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Belmaker, RH. The lessons of platelet monoamine oxidase. Psychol. Med. 14:249-253, 1984.
2. Blank, AM; Goldstein, SE; and Chatterjee, N. Pre-menstrual tension and mood change (Review). Can. J. Psychiatry 25(7):577-585, 1980.
3. Buchsbaum, MS, and Haier, RJ. Psychopathology: Biological approaches (Review). Ann. Rev. Psychology 34:401-430, 1983.
4. Bukhari, AR; Guessab, A; and Nicol, ML. Hormone mediated changes in monoamine stores and regulation of enzymes of biosynthesis and metabolism in the rat adrenal gland. Influence of progesterone, estradiol, ACTH, and testosterone administration. Steroids 38(1):1-10, 1981.
5. Cassano, GB; Musetti, L; Soriani, A; and Savino, M. The pharmacologic treatment of depression: Drug selection criteria (Review). Pharmacopsychiatry 26 (Supp. 1): 17-23, 1993.
6. Cesura, AM, and Pletscher, A. The new generation of monoamine oxidase inhibitors (Review). Prog. Drug Res. 38:171-297, 1992.
7. Chan-Palay, V. Depression and senile dementia of the Alzheimer type: A role for moclobemide (Review). Psychopharmacology 106(Suppl.):S137-S139,1992.
8. Chen, DT, and Ruch, R. Safety of moclobemide in clinical use (Review). Clin. Neuropharmacol. 16(Suppl. 2):S63-S68, 1993.
9. Chevillard, C; Barden, N; and Saavedra, JM. Estradiol treatment decreases type A and increases type B monoamine oxidase in specific brain stem areas and cerebellum of ovariectomized rats. Brain Res. 222(1):177-181, 1981.
10. Qarke, DE, and Sampath, SS. Effects of hypophysectomy, bilateral adrenalectomy, and hormone replacement therapy upon organ monoamine oxidase activity. Experientia 31(9):1098-1100, 1975.
11. DePrada, M; Cesura, AM; Launay, JM; and Richards, JG. Platelets as a model for neurones? (Review.) Experientia 44(2):115-126, 1988.
12. Delumeau, JC; Bentue-Ferrer, D; Gandon, JM; Amrein, R; Belliard, S; and Allain, H. Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases (Review). J. Neural Transm. Suppl. 41:259-266, 1994.
13. Dowson, JH. MAO inhibitors in mental disease: Their current status (Review). J. Neural Transm. Suppl. 23:121-138, 1987.
14. Feldman, JM, and Roche, J. Effect of oral contraceptives on platelet monoamine oxidase, monoamine excretion, and adrenocortical function. Clin. Pharmacol. Ther. 20(6):670-675, 1976.
15. Gereau, RW, 4th; Kedzie, KA; and Renner, KJ. Effect of progesterone on serotonin turnover in rats primed with estrogen implants into the ventromedial hypothalamus. Brain Res. Bull. 32:293-300, 1993.
16. Goff, DC; Renshaw, PF; Sarid-Segal, O; Dreyfuss, DA; Amico, ET; and Ciraulo, DA. A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. Biol. Psychiatry 33(10):700-706, 1993.
17. Gudeman, JH; Schatzberg, AF; Samson, JA; Orsulak, PJ; Cole, JO; and Schildkraut, JJ. Toward a biochemical classification of depressive disorders. VI: Platelet MAO activity and clinical symptoms in depressed patients. Am. J. Psychiatry 139:630-633, 1982.
18. Holsboer, F; Benkert, O; and Demisch, L. Changes in MAO activity during estrogen treatment of females with endogenous depression. Modern Prob. Pharmacopsychiatry 19:321-326, 1983.
19. Kampen, DL, and Sherwin, BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstet. Gynecol. 83(6):979-983, 1994.
20. Kanazawa, I. Short review on monoamine oxidase and its inhibitors (Review). Eur. Neurol. 34(Suppl. 3):36-39, 1994.
21. Klaiber, EL; Broverman, DM; Vogel, W; and Kobayashi, Y. Estrogen therapy for severe persistent depressions in women. Arch. Gen. Psychiatry 36:550-554, 1979.
22. Klaiber, EL; Broverman, DM; Vogel, W; Kobayashi, Y; and Moriarty, D. Effects of estrogen therapy on plasma MAO activity and EEG driving responses of depressed women. Am. J. Psychiatry 128(12):1492-1498, 1972.
23. Kopin, IJ. Monoamine oxidase and catecholamine metabolism (Review). J. Neural Transm. Suppl. 41:57-67, 1994.
24. LeWitt, PA. Neuroprotection by anti-oxidant strategies in Parkinson's disease (Review). Eur. Neurol. 33(Suppl. 1):24-30, 1993.
25. Luine, VN; Khylchevskaya, RI; and McEwen, BS. Effect of gonadal steroids on activities of monoamine oxidase and choline acetylase in rat brain. Brain Res. 86(2):293-306, 1975.
26. Luine, VN, and McEwen, BS. Effects of an estrogen antagonist on enzyme activities and [3H]estradiol nuclear binding in uterus, pituitary, and brain. Endocrinology 100(4):903-910, 1977.
27. Luine, VN, and Paden, CM. Effects of monoamine oxidase inhibition on female sexual behavior, serotonin levels and type A and B monoamine oxidase activity. Neuroendocrinology 34(4):245-251, 1982.
28. Luine, VN, and Rhodes, JC. Gonadal hormone regulation of MAO and other enzymes in hypothalamic areas. Neuroendocrinology 36(3):235-241, 1983.
29. Ma, ZQ; Violani, E; Villa, F; Picotti, GB; and Maggi, A. Estrogenic control of monoamine oxidase A activity in human neuroblastoma cells expressing physiological concentrations of estrogen receptor. Eur. J. Pharmacol. 284(1-2):171-176, 1995.
30. Mallet, J; Meloni, R; and Laurent, C. Catecholamine metabolism and psychiatric or behavioral disorders (Review). Curr. Opin. Genet. Dev. 4(3):419-426, 1994.
31. Montgomery, SA. Rapid onset of action of venlafaxine (Review). Int. Clin. Psychopharmacol. 10(Suppl. 2):21-27, 1995.
32. Nies, A; Robinson, DS; Harris, LS; and Lamborn, KR. Comparison of monoamine oxidase substrate activities in twins, schizophrenics, depressives, and controls. Adv. Biochem. Psychopharmacol. 12:59-70, 1974.
33. Nolen, WA; Haffmans, PM; Bouvy, PF; and Duivenvoorden, HJ. Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. J. Affect. Disord. 28(3):189-197, 1993a.
34. Nolen, WA; Hoencamp, E; Bouvy, PF; and Haffmans, PM. Reversible monoamine oxidase-A inhibitors in resistant major depression. Clin. Neuropharmacol. 15(Suppl. 1, Pt A):440A-431A, 1992.
35. Nolen, WA; Hoencamp, E; Bouvy, PF; and Haffmans, PM. Reversible monoamine oxidase-A inhibitors in resistant major depression (Review). Clin. Neuropharmacol. 16(Suppl. 2):S69-S76, 19936.
36. Norman, TR; Chamberlain, KG; French, MA; and Burrows, GD. Platelet monoamine oxidase activity and cigarette smoking. J. Affect. Disord. 4(1):73-77, 1982.
37. Ohkura, T; Isse, K; Akazawa, K; Hamamoto, M; Yaoi, Y; and Hagino, N. Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. Endocr. J. 41(4):361-371, 1994.
38. Olcese, JM; Hall, TR; Figueroa, HR; and deVlaming, VL. Effects of clomiphene citrate, a nonsteroidal antiestrogen, on brain monoaminergic mechanisms in female goldfish, Carassius auratus. Compar. Biochem. Physiol. - C. Compar. Pharmacol. Toxicol. 77(2):335-337, 1984.
39. Redmond, DE, Jr; Murphy, DL; Baltu, J; Ziegler, MG; and Lake, CR. Menstrual cycle and ovarian hormone effects on plasma and platelet monoamine oxidase (MAO) and plasma dopamine-beta-hydroxylase (DBH) activities in the rhesus monkey. Psychosom. Med. 7(5):417-428, 1975.
40. Richardson, JS. On the functions of monoamine oxidase, the emotions, and adaptation to stress (Review). Int. J. Neurosci. 70(1-2): 75-84, 1993.
41. Robinson, DS. Changes in monoamine oxidase and monoamines with human development and aging (Review). Federation Proc. 34(1): 103-107, 1975.
42. Robinson, DS, and Nies, A. Genetics of monoamine oxidase (Review). Modern Prob. Pharmacopsychiatry 10:57-64, 1975.
43. Rudorfer, MV. Monoamine oxidase inhibitors: Reversible and irre® versible. Psychopharmacol. Bull. 28(1):45-57, 1992.
44. Sandler, M; Reveley, MA; and Glover, V. Human platelet monoamine oxidase activity in health and disease: A review. J. Clin. Pathol. 34(3):292-302, 1981.
45. Saura, J; Luque, JM; Cesura, AM; DePrada, M; Chan-Palay, V; Huber, G; Loffler, J; and Richards, JG. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience 62(1):15-30, 1994.
46. Schildkraut, JJ; Orsulak, PJ; Schatzberg, AF; Gudeman, JE; Cole, JO; Rhode, WA; Labrie, RA. Toward a biochemical classification of depressive disorders. I. Differences in urinary MHPG and other catecholamine metabolites in clinically defined subtypes of depressions. Arch. Gen. Psychiatry 35:1427, 1978.
47. Sherwin, BB, and Suranyi-Cadotte, BE. Up-regulatory effect of estrogen on platelet 3H-imipramine binding sites in surgically menopausal women. Biol. Psychiatry 28:339-348, 1990.
48. Shih, JC. Molecular basis of human MAO A and B (Review). Neuropsychopharmacology 4(1):1-7, 1991.
49. Srivastava, K; Das Gupta, PK; and Mehrotra, PK. Monoamine oxidase activity in the pituitary of mice after estrogen, progesterone and centchroman treatment. Indian J. Physiol. Pharmacol. 22(3):310-312, 1978.
50. Trendelenburg, U. The interaction of transport mechanisms and intracellular enzymes in metabolizing systems (Review). J. Neural Transm. Suppl. 32:3-18, 1990.
51. Vaccari, A, and Biassoni, R. Gonadal influences on the inhibition of monoamine oxidase type B activity. J. Neurosci. Res. 8(1):13-19, 1982.
52. Vogel, W; Broverman, DM; Klaiber, EL; and Kobayashi, Y. EEG driving responses as a function of monoamine oxidase. Electroencephalography Clin. Neurophysiol. 36(2):205-207, 1974.
53. Wahlund, B; Saaf, J; and Wetterberg, L. Classification of patients with affective disorders using platelet monoamine oxidase activity, serum melatonin and postdexamethasone cortisol. Acta Psychiatr. Scand. 91(5):313-321, 1995.
54. Weyler, W; Hsu, YP; and Breakefield, XO. Biochemistry and genetics of monoamine oxidase (Review). Pharmacol. Ther. 47(3):391-417, 1990.
55. Wirz-Justice, A. Platelet research in psychiatry. (Review). Experientia 44(2):145-152, 1988.
56. Wyatt, RJ; Potkin, SG; and Murphy, DL. Platelet monoamine oxidase activity in schizophrenia: A review of the data. Am. J. Psychiatry 136(4A):377-385, 1979.
57. Youdim, MB. Platelet monoamine oxidase B: Use and misuse (Review). Experientia 44(2):137-141, 1988.
58. Zhu, QS; Grimsby, J; Chen, K; and Shih, JC. Promoter organization and activity of human monoamine oxidase (MAO) A and B genes. J. Neurosci. 12(11):4437-4446, 1992.